Tauriga Sciences Inc. to Present at Marijuana for Medical Professionals Conference on September 9 in Denver, Colorado

DENVER and LOS ANGELES, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that the Company's Chief Medical Officer, Lawrence A. May, M.D., F.A.C.P., will make a presentation on Tuesday, September 9th, 2014 at 12:15 PM at Marijuana for Medical Professionals Conference being held at the Sherman St Event Center in Denver, CO.

Dr. May, a Phi Beta Kappa graduate of Harvard and Harvard Medical School, has written books and lectured around the world. The presentation, entitled "Medical Marijuana: Gateway to Natural Health Enhancement," will feature information about benefits of topical cannabis and will discuss ways to support the body's endocannabinoid system through natural dietary supplements. Dr. May will discuss the potential of topical cannabis for local muscular pain relief and improvement in skin, with a review of clinical experience particularly in the senior population. He will also highlight the potential for the medical marijuana dispensary as a locus to provide dietary supplements that are complementary to and synergistic with cannabis for the alleviation of pain, anxiety and sleep disorders.

Tauriga's Chief Medical Officer Lawrence A. May, M.D., F.A.C.P. states, "We are pleased to present at this educational conference for physicians and other medical professionals. Greater insight and understanding of the pharmacological properties of medical marijuana will translate to improved patient outcomes, and we believe that medical marijuana will lead to broader opportunities for encouraging and maintaining natural wellness."

"We are honored to have Dr. May present at the conference," commented Martha Montemayor, Partner and General Manager of Healthy Choices Unlimited and conference organizer. "Dr. May and Tauriga CEO Dr. Stella M. Sung have demonstrated a strong commitment to promoting clinical and scientific understanding of medical marijuana."

Dr. May's presentation will immediately follow the conference's keynote presentation by Raphael Mechoulam, Ph.D., one of the most recognized scientists in cannabis research. Dr. Mechoulam is renowned for the isolation, structure elucidation and total synthesis of Δ9-tetrahydrocannabinol (THC), the principal psychoactive component of marijuana.

For information on the conference, please visit www.mmjfordoctors.com or contact Martha Montemayor at mmjfordoctors@gmail.com

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a diversified portfolio of life science assets that is capital efficient and has the potential to generate meaningful profitable revenues. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On July 15, 2014, Tauriga acquired a California based topical cannabis cream company. Please visit the Company's corporate website at www.tauriga.com.


This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.


Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

CONTACT: Tauriga Sciences, Inc.: Dr. Stella M. Sung, Chairman and Chief Executive Officer Tauriga Sciences, Inc. www.tauriga.com San Diego: + 1-858-353-5749 Montreal: + 1-514-840-3697 Email: ssung@tauriga.com

Source:Tauriga Sciences Inc